EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mass screening of hepatitis B and C in Burkina Faso: seroprevalence update and impact of hepatitis B vaccine

Armel Moumouni Sanou, Delphine Napon-Zongo, Abou Coulibaly, Ina Marie Angèle Traore, Ad Bafa Ibrahim Ouattara, Abdoul Kader Ilboudo, Abdou Azaque Zoure, Sylvie Zida, Mathuola Nina Geneviève Ouattara, Abdoulaye Dera, Djara Konate, Eric Kyelem und 4 weitere

The Journal of Infection in Developing Countries · 2024

DOI: 10.3855/jidc.19673 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2024. Verfasst von Armel Moumouni Sanou und 15 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo…. Hauptthemen laut MEDLINE: Hepatitis B, Hepatitis B Vaccines, Hepatitis C, Mass Screening. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Updated data on the seroprevalences of hepatitis B and C viruses (HBV, HCV) are required to enable the adaptation of control strategies. In this study, we aimed to: (i) estimate the seroprevalences of HBsAg carriers and HCV exposure in the general population, and (ii) determine the impact of vaccination on HBV circulation since its introduction in 2006 in the Expanded Program on Immunization (EPI). Methodology: From October 2020 to October 2022, a mass screening campaign was conducted in 10 cities across Burkina Faso. Individuals of all ages and genders who consented to participate were screened for viral markers (HBsAg, anti-HCV) using rapid diagnostic tests. The proportions of HBsAg carriers and HCV exposure were calculated using Stata, and logistic regression was used to assess the impact of HBV vaccination on HBsAg carriage.

Results

A total of 15,650 participants were enrolled in the study. Of these, 51.4% were women and the age range was from 1 to 97 years. All participants were screened for HBsAg and 7,507 were also screened for anti-HCV. Overall, the seroprevalence of HBsAg was 8.8% and 2.6% for anti-HCV. The results indicated that age, gender, and place of residence were associated with HBV infection.

Conclusions

The prevalence of HBV and HCV infections remains high in Burkina Faso. Prevention strategies, including initial mass screening with rapid diagnostic tests and vaccination, need to be intensified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis BHepatitis B VaccinesHepatitis CMass ScreeningHumansBurkina FasoSeroepidemiologic StudiesFemaleMaleAdultAdolescentMiddle AgedYoung AdultChild, PreschoolChildInfantAgedAged, 80 and overHepatitis B Surface Antigens

Stichwörter der Autor:innen

Burkina FasoHepatitis Bepidemiologyhepatitis Cmass screeningseroprevalence

Substanzen

Hepatitis B VaccinesHepatitis B Surface Antigens

Autor:innen und Institutionen

  • Laboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo-Dioulasso, Burkina Faso.
  • Institut Supérieur des Sciences de la Santé (INSSA), Université Nazi Boni, Bobo-Dioulasso, Burkina Faso.
  • Laboratoire de Recherche en Santé Publique et Nutrition (LR-SPN), Institut de Recherche en Sciences de la Santé (IRSS), Burkina Faso.
  • Département Clinique, Centre Assaut-Hépatites, Bobo-Dioulasso, Burkina Faso.
  • Département des laboratoires, Centre Assaut-Hépatites, Bobo-Dioulasso, Burkina Faso.
  • Centre MURAZ, Institut National de Santé Publique, Burkina Faso.

Zitieren

APA

Sanou, A. M., Napon-Zongo, D., Coulibaly, A., Traore, I. M. A., Ouattara, A. B. I., Ilboudo, A. K., Zoure, A. A., Zida, S., Ouattara, M. N. G., Dera, A., Konate, D., Kyelem, E., Nikiema, A. S., Lankoande, D., Ilboudo, D., & Kania, D. (2024). Mass screening of hepatitis B and C in Burkina Faso: seroprevalence update and impact of hepatitis B vaccine. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.19673

Vancouver

Sanou AM, Napon-Zongo D, Coulibaly A, Traore IMA, Ouattara ABI, Ilboudo AK, et al. Mass screening of hepatitis B and C in Burkina Faso: seroprevalence update and impact of hepatitis B vaccine. The Journal of Infection in Developing Countries. 2024. doi:10.3855/jidc.19673

BibTeX
@article{Sanou2024,
  author = {Sanou, Armel Moumouni and Napon-Zongo, Delphine and Coulibaly, Abou and Traore, Ina Marie Angèle and Ouattara, Ad Bafa Ibrahim and Ilboudo, Abdoul Kader and Zoure, Abdou Azaque and Zida, Sylvie and Ouattara, Mathuola Nina Geneviève and Dera, Abdoulaye and Konate, Djara and Kyelem, Eric and Nikiema, Achille Sindimbasba and Lankoande, David and Ilboudo, Dieudonné and Kania, Dramane},
  title = {Mass screening of hepatitis B and C in Burkina Faso: seroprevalence update and impact of hepatitis B vaccine},
  journal = {The Journal of Infection in Developing Countries},
  year = {2024},
  doi = {10.3855/jidc.19673}
}
Kostenlos starten →